A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases

Primo N Lara, Walter M. Stadler, Jeff Longmate, David I. Quinn, Jason Wexler, Marta Van Loan, Przemyslaw Twardowski, Paul H. Gumerlock, Nicholas J. Vogelzang, Everett E. Vokes, Heinz Josef Lenz, James H. Doroshow, David R Gandara

Research output: Contribution to journalArticlepeer-review

55 Scopus citations

Fingerprint Dive into the research topics of 'A randomized phase II trial of the matrix metalloproteinase inhibitor BMS-275291 in hormone-refractory prostate cancer patients with bone metastases'. Together they form a unique fingerprint.

Medicine & Life Sciences